These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Ancillary benefits of Mycobacterium avium-intracellulare complex prophylaxis with clarithromycin in HIV-infected patients. Jablonowski H; Fätkenheuer G; Youle M; Newell T; Lines S; Craft JC Drugs; 1997; 54 Suppl 2():16-22; discussion 28-9. PubMed ID: 9358196 [TBL] [Abstract][Full Text] [Related]
24. Treatment and prophylaxis of disseminated Mycobacterium avium complex in HIV-infected individuals. Faris MA; Raasch RH; Hopfer RL; Butts JD Ann Pharmacother; 1998 May; 32(5):564-73. PubMed ID: 9606478 [TBL] [Abstract][Full Text] [Related]
25. Another perspective on MAC prophylaxis. Interview by Gordon Nary. Pierce M J Int Assoc Physicians AIDS Care; 1995 Aug; 1(7):16-8. PubMed ID: 11362746 [TBL] [Abstract][Full Text] [Related]
26. Interventions for the prevention of mycobacterium avium complex in adults and children with HIV. Uthman MM; Uthman OA; Yahaya I Cochrane Database Syst Rev; 2013 Apr; (4):CD007191. PubMed ID: 23633339 [TBL] [Abstract][Full Text] [Related]
27. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Karakousis PC; Moore RD; Chaisson RE Lancet Infect Dis; 2004 Sep; 4(9):557-65. PubMed ID: 15336223 [TBL] [Abstract][Full Text] [Related]
28. Quantitative cultures and drug susceptibility testing of Mycobacterium avium clinical isolates before and during the antimicrobial therapy. Heifets LB Res Microbiol; 1994; 145(3):188-96. PubMed ID: 7809471 [No Abstract] [Full Text] [Related]
29. Incidence of disseminated Mycobacterium avium-complex infection in HIV patients receiving antiretroviral therapy with use of Mycobacterium avium-complex prophylaxis. Jung Y; Song KH; Choe PG; Park WB; Bang JH; Kim ES; Kim HB; Park SW; Kim NJ; Oh MD Int J STD AIDS; 2017 Dec; 28(14):1426-1432. PubMed ID: 28592210 [TBL] [Abstract][Full Text] [Related]
30. Prevention of the selection of clarithromycin-resistant Mycobacterium avium-intracellulare complex. Grosset J; Ji B Drugs; 1997; 54 Suppl 2():23-7; discussion 28-9. PubMed ID: 9358197 [TBL] [Abstract][Full Text] [Related]
31. A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation. Carter G; Young LS; Bermudez LE Antimicrob Agents Chemother; 2004 Dec; 48(12):4907-10. PubMed ID: 15561879 [TBL] [Abstract][Full Text] [Related]
32. Comparison of clarithromycin-sensitive and clarithromycin-resistant Mycobacterium avium strains isolated from AIDS patients during therapy regimens including clarithromycin. Matsiota-Bernard P; Zinzendorf N; Onody C; Guenounou M J Infect; 2000 Jan; 40(1):49-54. PubMed ID: 10762111 [TBL] [Abstract][Full Text] [Related]
35. Activity of antimicrobial agents against Mycobacterium avium-intracellulare complex (MAC) strains isolated in Italy from AIDS-patients. Fattorini L; Hu CQ; Jin SH; Santoro C; Tsang AY; Mascellino MT; Mandler F; Orefici G Zentralbl Bakteriol; 1992 Apr; 276(4):512-20. PubMed ID: 1611208 [TBL] [Abstract][Full Text] [Related]
36. A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. Dunne M; Fessel J; Kumar P; Dickenson G; Keiser P; Boulos M; Mogyros M; White AC; Cahn P; O'Connor M; Lewi D; Green S; Tilles J; Hicks C; Bissett J; Schneider MM; Benner R Clin Infect Dis; 2000 Nov; 31(5):1245-52. PubMed ID: 11073759 [TBL] [Abstract][Full Text] [Related]
37. Clofazimine as prophylaxis for disseminated Mycobacterium avium complex infection in AIDS. Abrams DI; Mitchell TF; Child CC; Shiboski SC; Brosgart CL; Mass MM J Infect Dis; 1993 Jun; 167(6):1459-63. PubMed ID: 8501340 [TBL] [Abstract][Full Text] [Related]
38. Azithromycin in the prophylaxis of opportunistic infections in AIDS. McCutchan JA Int J STD AIDS; 1996; 7 Suppl 1():34-7. PubMed ID: 8652726 [TBL] [Abstract][Full Text] [Related]
39. Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART? Yangco BG; Buchacz K; Baker R; Palella FJ; Armon C; Brooks JT; AIDS Patient Care STDS; 2014 Jun; 28(6):280-3. PubMed ID: 24833016 [TBL] [Abstract][Full Text] [Related]
40. The role of advanced generation macrolides in the prophylaxis and treatment of Mycobacterium avium complex (MAC) infections. Amsden GW; Peloquin CA; Berning SE Drugs; 1997 Jul; 54(1):69-80. PubMed ID: 9211081 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]